ARTICLE | Clinical News
Portola's Factor Xa antidote meets Phase III endpoint
January 9, 2015 8:00 AM UTC
Portola Pharmaceuticals Inc. (NASDAQ:PTLA) gained $2.01 to $30.33 on Friday after its andexanet alfa met the primary endpoint in the first part of the Phase III ANNEXA-R study to reverse the anticoagulant activity of Xarelto rivaroxaban from Bayer AG (Xetra:BAYN) and partner Johnson & Johnson (NYSE:JNJ).
Portola said an 800 mg IV bolus of andexanet alfa significantly and immediately reversed anticoagulant activity of Xarelto compared to placebo as measured by anti- Factor Xa levels. Portola will present full trial data at the American College of Cardiology meeting in March. ...